Log in

MAB Mabion SA GPW · Poland

Mabion SA (MAB) news

Mabion SA is a public biotech or pharmaceutical company listed on GPW under the ticker MAB, recorded under Poland. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Mabion SA news

We have not published a story on Mabion SA yet. When there is news, it will appear here.

Questions about Mabion SA

What is the ticker symbol of Mabion SA?

Mabion SA trades under the ticker MAB on GPW.

Where is Mabion SA listed?

Mabion SA is listed on GPW. Our directory also records these other listings: GETTEX:272.

Which country or territory is Mabion SA listed under?

Our directory records Mabion SA under Poland.

What does Mabion SA do?

Our directory classifies Mabion SA as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Mabion SA?

The ISIN recorded for Mabion SA is PLMBION00016.

Does aibio.space cover Mabion SA?

aibio.space lists Mabion SA among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Mabion SA?

Companies in our directory listed in the same country and business area as Mabion SA: Selvita SA, QNA Technology SA, genXone SA, Adiuvo Investment, Read-Gene SA, MultiQure.

Investor discussion: Mabion SA

Members talk about Mabion SA (MAB). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open GPW:MAB on TradingView.

Listing details

Mabion SA is a public biotech or pharmaceutical company listed on GPW under the ticker MAB, recorded under Poland. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Mabion SA
Ticker
MAB
Listing
GPW
Country or territory
Poland
Business scope
Biotechnology
ISIN
PLMBION00016
Other listed symbols
GETTEX:272
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.